

Supporting Information

Efficient one-step synthesis of 3-(indol-2-yl)quinoxalin-2(*1H*)-ones via electrochemical oxidative cross-dehydrogenative coupling

Hao Zhang,^a Lishan Hu,^a Kai Yu,^{*b} Lan-Lan Lou^{*a} and Shuangxi Liu^a

^aSchool of Materials Science and Engineering & National Institute of Advanced Materials Nankai University, Tianjin 300350, China. E-mail: llou@nankai.edu.cn.

^bMOE Key Laboratory of Pollution Processes and Environmental Criteria Tianjin Key Laboratory of Environmental Technology for Complex Trans-Media Pollution College of Environmental Science and Engineering Nankai University, Tianjin 300350, China. E-mail: kaiyu@nankai.edu.cn.


Contents

1. General information.....	S2
2. General procedure for the synthesis of compounds 3aa-3ar and 3ba-3ma	S2
3. Gram-scale experiment.....	S2
4. Product transformation experiment.....	S3
5. Characterization data of 3aa-3ar , 3ba-3ma and 4	S3
6. Copies of NMR spectra for prepared compounds.....	S13
7. References.....	S41

1. General information


Unless otherwise specially stated, all reagents were purchased from commercial supplies and all solvents were used without any purification. Thin-layer chromatography (TLC) was performed to monitor reaction progress on silica gel GF254 plates (0.2 mm thick, Qingdao Haiyang Chemical Co., Ltd.) and all compounds were visualized with a UV light of 254 nm and 365 nm. NMR spectra were recorded on a Bruker Avance III spectrometer operating at 400 MHz (^1H NMR) and 101 MHz (^{13}C NMR). Chemical shifts were reported in ppm downfield and referenced as follows: ^1H : residual internal DMSO (δ 2.51 ppm); ^{13}C : internal DMSO (δ 39.6 ppm). Coupling constants were quoted in Hz (J). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet).

2. General procedure for the synthesis of compounds 3aa-3ar and 3ba-3ma



An undivided cell was equipped with a graphite rod ($\Phi = 5$ mm) anode and a Pt plate (1.0 cm \times 1.0 cm) cathode and connected to a DC regulated power supply. To the cell was added quinoxalinone **1** (0.25 mmol, 1.0 equiv.), indole or pyrrole **2** (0.35 mmol, 1.4 equiv.), LiClO₄ (0.5 mmol), and CH₃CN (5.0 mL). The mixture was stirred for 15 minutes at 30 °C, then electrolyzed under a constant current of 4.5 mA for 1.5 hours. After the reaction was completed, the mixture was sonicated for 1 minute to remove the reactants and products adsorbed on electrodes, and then filtered. The residue was washed with cool CH₃CN (3 \times 1.0 mL) and deionized water (3 \times 1.0 mL) to remove the excess indole and electrolyte. The product was dried under vacuum for 24 hours.


3. Gram-scale experiment



An undivided cell was equipped with a graphite plate (2.0 \times 2.0 cm) anode and a Pt plate (2.0 cm \times 2.0 cm) cathode and connected to a DC regulated power supply. To the cell was added quinoxalin-2(1H)-one **1a** (5.0 mmol, 1.0 equiv.), indole **2a** (7.0 mmol, 1.4 equiv.), LiClO₄ (10 mmol), and CH₃CN (100 mL). The mixture was stirred for 15 minutes at 30 °C, then electrolyzed under a constant current of 18.0 mA. After the reaction was completed, the


mixture was sonicated for 1 minute to remove the reactants and products adsorbed on electrodes, and then filtered. The residue was washed with cool CH₃CN (3 × 20 mL) and deionized water (3 × 20 mL) to remove the excess indole and electrolyte. The product was dried under vacuum for 24 hours.

4. Product transformation experiment




A 10 mL reaction tube was added **3da** (0.1 mmol, 1.0 equiv.), CuTc (0.004 mmol, 0.04 equiv.) and toluene (1.0 mL), and the mixture was stirred for 15 min at room temperature, followed by addition of TsN₃ (0.12 mmol, 1.2 equiv.) via a syringe. The resulting mixture was stirred at room temperature for 24 hours. Then the reaction mixture was filtered and the residue was washed with toluene (3×1.0 mL) to remove the excess TsN₃ and catalyst. The residue was dried under vacuum at room temperature for 24 hours.

5. Characterization data of 3aa-3ar, 3ba-3ma and 4



3-(1H-indol-3-yl)quinoxalin-2(1H)-one (3aa)¹


Following the general procedure, the desired compound was obtained as a yellow solid, mp 330-331 °C, 50 mg, 77% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.41 (s, 1H), 11.79 (s, 1H), 8.95 (d, *J* = 2.9 Hz, 1H), 8.93-8.84 (m, 1H), 7.87 (d, *J* = 7.9 Hz, 1H), 7.52 (dd, *J* = 5.8, 2.6 Hz, 1H), 7.43 (dd, *J* = 11.0, 4.2 Hz, 1H), 7.31 (dd, *J* = 11.7, 4.5 Hz, 2H), 7.24 (m, 2H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.88, 152.46, 136.75, 133.54, 133.12, 130.65, 128.40, 128.05, 126.68, 123.66, 123.45, 123.00, 121.45, 115.39, 112.34, 111.81.



3-(1-methyl-1H-indol-3-yl)quinoxalin-2(1H)-one (3ab)¹


Following the general procedure, the desired compound was obtained as a yellow solid, mp 286-287 °C, 56 mg, 81% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.46 (s, 1H), 8.95 (d, *J* = 2.4 Hz, 1H), 8.90 (t, *J*

= 4.8 Hz, 1H), 7.87 (dd, J = 7.4, 2.3 Hz, 1H), 7.62-7.52 (m, 1H), 7.44 (dd, J = 8.7, 6.5 Hz, 1H), 7.38-7.22 (m, 4H), 3.93 (s, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 154.43, 151.73, 136.93, 136.90, 132.74, 130.24, 128.05, 127.65, 126.76, 123.32, 123.21, 122.71, 121.37, 115.01, 110.39, 110.27, 33.10.




3-(2-methyl-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ac)¹

Following the general procedure, the desired compound was obtained as a yellow solid, mp 290-292 °C, 60 mg, 87% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 12.33 (s, 1H), 11.49 (s, 1H), 7.78 (dd, J = 13.8, 7.8 Hz, 2H), 7.46 (t, J = 7.2 Hz, 1H), 7.31 (dt, J = 15.3, 6.8 Hz, 3H), 7.05 (dt, J = 14.3, 6.9 Hz, 2H), 2.56 (s, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 154.67, 154.63, 139.40, 135.22, 132.61, 131.36, 128.78, 128.04, 127.94, 123.14, 120.91, 119.60, 114.98, 110.64, 109.24, 14.35.




3-(2-phenyl-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ad)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 347-350 °C, 70 mg, 83% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 12.27 (s, 1H), 11.83 (s, 1H), 7.73 (dd, J = 14.8, 7.9 Hz, 2H), 7.50 (dd, J = 13.9, 7.8 Hz, 4H), 7.39 (t, J = 7.4 Hz, 2H), 7.31 (q, J = 7.2 Hz, 3H), 7.19 (t, J = 7.4 Hz, 1H), 7.08 (t, J = 7.4 Hz, 1H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 155.18, 154.08, 139.40, 136.08, 133.39, 132.50, 131.85, 129.42, 128.60, 128.43, 128.29, 127.78, 123.13, 122.12, 120.24, 120.08, 115.11, 111.50, 108.67. HRMS (ESI) m/z calculated for $\text{C}_{22}\text{H}_{16}\text{N}_3\text{O}$ ($\text{M}+\text{H}$)⁺: 338.1288. Found: 338.1289.




3-(5-methoxy-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ah)¹

Following the general procedure, the desired compound was obtained as a yellow solid, mp 319-321 °C, 66 mg, 91% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 12.39 (s, 1H), 11.67 (s, 1H), 8.89 (d, J = 3.0 Hz, 1H), 8.46 (d, J = 2.5 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.53-7.19 (m, 4H), 6.89 (dd, J = 8.7, 2.6 Hz, 1H), 3.88 (s, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 154.98, 154.52, 152.13, 133.52, 132.72, 131.26, 130.19, 127.91, 127.63, 126.99, 123.30, 115.00, 112.56, 112.15, 111.15, 105.18, 55.34.




3-(5-(benzyloxy)-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ai)²

Following the general procedure, the desired compound was obtained as a solid, mp 274-276 °C, 58 mg, 63% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.37 (s, 1H), 11.67 (s, 1H), 8.88 (d, *J* = 3.0 Hz, 1H), 8.49 (d, *J* = 2.6 Hz, 1H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.56 (d, *J* = 7.1 Hz, 2H), 7.46-7.37 (m, 4H), 7.37-7.26 (m, 3H), 6.96 (dd, *J* = 8.7, 2.5 Hz, 1H), 5.24 (s, 2H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.48, 154.00, 152.03, 137.99, 133.56, 132.68, 131.38, 130.16, 128.47, 127.89, 127.69, 127.64, 126.89, 123.24, 114.95, 112.89, 112.57, 111.17, 106.58, 69.82.




3-(5-fluoro-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3aj)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 296-298 °C, 48 mg, 69% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.44 (s, 1H), 11.88 (s, 1H), 8.98 (d, *J* = 3.0 Hz, 1H), 8.56 (d, *J* = 10.6 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 1H), 7.52 (dd, *J* = 8.8, 4.7 Hz, 1H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.32 (t, *J* = 7.3 Hz, 2H), 7.09 (dd, *J* = 13.9, 5.6 Hz, 1H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 158.25 (d, *J* = 232.4 Hz), 154.38, 151.81, 134.66, 132.97, 132.58, 130.27, 128.19, 127.71, 126.70 (d, *J* = 11.0 Hz), 123.32, 115.03, 113.01 (d, *J* = 9.9 Hz), 111.42 (d, *J* = 4.1 Hz), 110.63 (d, *J* = 26.0 Hz), 107.78 (d, *J* = 24.4 Hz). HRMS (ESI) m/z calculated for C₁₆H₁₁FN₃O (M+H)⁺: 280.0881. Found: 280.0881.




3-(5-chloro-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ak)¹

Following the general procedure, the desired compound was obtained as a yellow solid, mp 312-314 °C, 52 mg, 71% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.48 (s, 1H), 11.97 (s, 1H), 8.98 (d, *J* = 3.0 Hz, 1H), 8.86 (d, *J* = 2.2 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.55 (d, *J* = 8.6 Hz, 1H), 7.46 (t, *J* = 7.6 Hz, 1H), 7.33 (t, *J* = 7.2 Hz, 2H), 7.27 (dd, *J* = 8.6, 2.2 Hz, 1H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.35, 151.70, 134.85, 134.40, 132.51, 130.32, 128.34, 127.70, 127.32, 125.71, 123.38, 122.56, 122.00, 115.07, 113.54, 110.98.




3-(6-chloro-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3al)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 308-310 °C, 52 mg, 71% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.46 (s, 1H), 11.88 (s, 1H), 8.95 (d, *J* = 2.9 Hz, 1H), 8.85 (d, *J* = 8.6 Hz, 1H), 7.88 (dd, *J* = 7.2, 1.9 Hz, 1H), 7.57 (d, *J* = 1.7 Hz, 1H), 7.48-7.41 (m, 1H), 7.33 (d, *J* = 7.6 Hz, 2H), 7.25 (dd, *J* = 8.6, 1.9 Hz, 1H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.37, 151.70, 136.88, 133.96, 132.56, 130.38, 128.35, 127.77, 127.20, 125.04, 124.31, 123.35, 121.23, 115.07, 111.70, 111.44. HRMS (ESI) m/z calculated for C₁₆H₁₁ClN₃O (M+H)⁺: 296.0585. Found: 296.0588.



3-(7-methyl-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3am)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 284-286 °C, 52 mg, 75% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.40 (s, 1H), 11.78 (s, 1H), 8.93 (d, *J* = 3.0 Hz, 1H), 8.72 (d, *J* = 7.9 Hz, 1H), 7.86 (d, *J* = 7.6 Hz, 1H), 7.54-7.39 (m, 1H), 7.38-7.30 (m, 2H), 7.14 (t, *J* = 7.5 Hz, 1H), 7.05 (d, *J* = 7.2 Hz, 1H), 2.54 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.51, 152.03, 135.76, 132.81, 132.72, 130.24, 127.99, 127.64, 126.04, 123.25, 121.25, 120.98, 120.69, 114.98, 111.81, 16.83. HRMS (ESI) m/z calculated for C₁₇H₁₄N₃O (M+H)⁺: 276.1131. Found: 276.1131.




3-(7-methoxy-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3an)¹

Following the general procedure, the desired compound was obtained as a yellow solid, mp 325-327 °C, 48 mg, 66% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.39 (s, 1H), 11.90 (s, 1H), 8.82 (d, *J* = 3.0 Hz, 1H), 8.44 (d, *J* = 8.0 Hz, 1H), 7.85 (d, *J* = 7.9 Hz, 1H), 7.48-7.37 (m, 1H), 7.31 (d, *J* = 7.6 Hz, 2H), 7.16 (t, *J* = 7.9 Hz, 1H), 6.83 (d, *J* = 7.7 Hz, 1H), 3.97 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.47, 152.03, 146.20, 132.70, 132.41, 130.25, 128.05, 127.79, 127.66, 126.30, 123.28, 121.72, 115.75, 115.00, 111.96, 103.40, 55.32.




3-(7-(benzyloxy)-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3ao)¹

Following the general procedure, the desired compound was obtained as a yellow solid, mp 281-283 °C, 47 mg, 51% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.41 (s, 1H), 11.90 (s, 1H), 8.84 (d, *J* = 3.0 Hz, 1H), 8.46 (d, *J* = 8.0 Hz, 1H), 7.85 (d, *J* = 7.9 Hz, 1H), 7.60 (d, *J* = 7.1 Hz, 2H), 7.47-7.40 (m, 3H), 7.40-7.35 (m, 1H), 7.35-7.28 (m, 2H), 7.14 (t, *J* = 7.9 Hz, 1H), 6.93 (d, *J* = 7.8 Hz, 1H), 5.31 (s, 2H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 154.52, 152.05, 145.26, 137.28, 132.74, 132.62, 130.28, 128.54, 128.12, 128.02, 127.96, 127.86, 127.71, 126.54, 123.35, 121.72, 116.00, 115.05, 112.00, 104.77, 99.63, 69.47.




3-(1*H*-pyrrol-3-yl)quinoxalin-2(*1H*)-one (3ap)¹

Following the general procedure, the desired compound was obtained as a yellow solid, mp 246-248 °C, 42 mg, 80% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.44 (s, 1H), 11.66 (s, 1H), 7.72-7.70 (m, 1H), 7.44-7.40 (m, 2H), 7.31-7.26 (m, 2H), 7.06 (s, 1H), 6.23 (s, 1H). ¹³C NMR (101 MHz, *d*₆-DMSO): δ 153.85, 146.54, 132.38, 130.86, 128.31, 128.23, 127.40, 123.77, 123.49, 115.87, 115.19, 109.97.




3-(1-methyl-1*H*-pyrrol-3-yl)quinoxalin-2(*1H*)-one (3aq)¹

Following the general procedure, the desired compound was obtained as a light yellow solid, mp 213-214 °C, 39 mg, 69% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.35 (s, 1H), 7.71 (d, *J* = 7.9 Hz, 1H), 7.55 (dd, *J* = 4.0, 1.8 Hz, 1H), 7.46-7.38 (m, 1H), 7.27 (d, *J* = 7.8 Hz, 2H), 7.09 (t, *J* = 2.2 Hz, 1H), 6.14 (dd, *J* = 4.0, 2.6 Hz, 1H), 4.05 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 153.79, 147.85, 131.77, 130.75, 130.05, 128.64, 127.81, 127.15, 123.24, 118.75, 114.93, 107.51, 38.24.




3-(2,4-dimethyl-1*H*-pyrrol-3-yl)quinoxalin-2(*1H*)-one (3ar)¹

Following the general procedure, the desired compound was obtained as an orange solid, mp 200-201 °C, 50 mg, 84% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.51 (s, 1H), 11.37 (s, 1H), 7.63 (d, *J* = 7.9 Hz, 1H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.27 (d, *J* = 7.9 Hz, 2H), 5.89 (s, 1H), 2.50 (s, 3H), 2.28 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 155.34, 146.78, 133.13, 131.21, 129.61, 127.48, 127.25, 126.92, 123.63, 115.06, 111.98, 15.24, 13.09.




3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(1*H*)-one (3ba)²

Following the general procedure, the desired compound was obtained as a yellow solid, mp 220-223 °C, 56 mg, 81% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 11.79 (s, 1H), 8.93 (d, *J* = 3.0 Hz, 1H), 8.92-8.87 (m, 1H), 7.95-7.90 (m, 1H), 7.60-7.48 (m, 3H), 7.40 (ddd, *J* = 8.2, 6.0, 2.3 Hz, 1H), 7.28-7.20 (m, 2H), 3.75 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 153.80, 150.75, 136.41, 133.30, 133.09, 131.61, 128.50, 128.42, 126.43, 123.59, 123.14, 122.68, 121.13, 114.57, 112.02, 111.53, 29.24.



1-benzyl-3-(1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ca)²


Following the general procedure, the desired compound was obtained as a yellow solid, mp 202-204 °C, 75 mg, 85% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 11.84 (s, 1H), 8.96 (d, *J* = 2.8 Hz, 1H), 8.94-8.90 (m, 1H), 7.96 (d, *J* = 7.8 Hz, 1H), 7.53 (dt, *J* = 6.1, 3.6 Hz, 1H), 7.43 (t, *J* = 6.6 Hz, 2H), 7.40-7.20 (m, 8H), 5.64 (s, 2H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 152.86, 150.55, 136.40, 133.41, 133.27, 129.92, 128.67, 128.44, 126.31, 123.99, 123.04, 122.75, 121.22, 114.75, 112.03, 111.29, 78.44, 75.12, 31.42.



3-(1*H*-indol-3-yl)-1-(prop-2-yn-1-yl)quinoxalin-2(1*H*)-one (3da)


Following the general procedure, the desired compound was obtained as a yellow solid, mp 229-231 °C, 69 mg, 92% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 11.84 (s, 1H), 8.92 (d, *J* = 2.5 Hz, 1H), 8.91-8.85 (m, 1H), 7.97 (d, *J* = 7.9 Hz, 1H), 7.60 (q, *J* = 8.6 Hz, 2H), 7.56-7.49 (m, 1H), 7.44 (t, *J* = 7.5 Hz, 1H), 7.34-7.16 (m, 2H), 5.22 (s, 2H), 3.35 (s, 1H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 152.83, 150.52,

136.38, 133.38, 133.25, 129.89, 128.64, 128.40, 126.28, 123.95, 123.02, 122.71, 121.18, 114.71, 112.00, 111.27, 78.41, 75.09, 31.39. HRMS (ESI) m/z calculated for $C_{19}H_{14}N_3O$ ($M+H$)⁺: 300.1131. Found: 300.1135.




6-chloro-3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(1*H*)-one (3ea)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 265-267 °C, 53 mg, 65% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 11.82 (s, 1H), 8.92 (d, *J* = 3.0 Hz, 1H), 8.89-8.81 (m, 1H), 7.90 (d, *J* = 8.5 Hz, 1H), 7.62 (d, *J* = 2.2 Hz, 1H), 7.55-7.49 (m, 1H), 7.40 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.29-7.19 (m, 2H), 3.71 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 153.49, 150.73, 136.38, 133.55, 132.56, 132.40, 131.82, 129.73, 126.31, 123.45, 123.08, 122.69, 121.16, 114.24, 111.99, 111.35, 29.34. HRMS (ESI) m/z calculated for $C_{17}H_{13}ClN_3O$ ($M+H$)⁺: 310.0742. Found: 310.0748.



6-bromo-3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(1*H*)-one (3fa)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 286-288 °C, 43 mg, 49% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 11.83 (s, 1H), 8.93 (d, *J* = 3.0 Hz, 1H), 8.89-8.82 (m, 1H), 7.85 (d, *J* = 8.5 Hz, 1H), 7.77 (d, *J* = 2.0 Hz, 1H), 7.53 (ddd, *J* = 6.4, 5.8, 1.7 Hz, 2H), 7.30-7.20 (m, 2H), 3.72 (s, 3H). ¹³C NMR (101 MHz, *d*₆-DMSO) δ 153.56, 150.96, 136.46, 133.68, 132.83, 132.19, 130.03, 126.43, 126.37, 123.16, 122.82, 121.30, 121.00, 117.14, 112.10, 111.47, 29.42. HRMS (ESI) m/z calculated for $C_{17}H_{13}BrN_3O$ ($M+H$)⁺: 354.0237. Found: 354.0243.




3-(1*H*-indol-3-yl)-6-methylquinoxalin-2(1*H*)-one (3ga)

3-(1*H*-indol-3-yl)-7-methylquinoxalin-2(1*H*)-one (3ga')


Following the general procedure, the desired compound was obtained as a pale yellow solid, mp 224-226 °C, 60 mg, 87% yield. ¹H NMR (400 MHz, *d*₆-DMSO) δ 12.34 (s, 1H), 11.78 (d, *J* = 10.0 Hz, 1H), 8.99-8.79 (m, 2H), 7.80-7.68 (m, 1H), 7.51 (dt, *J* = 7.1, 2.4 Hz, 1H), 7.29-7.18 (m, 3H), 7.14 (dd, *J* =

10.6, 2.5 Hz, 1H), 2.42 (d, J = 2.5 Hz, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 154.65, 154.45, 152.04, 151.14, 138.04, 136.39, 133.06, 132.76, 132.72, 132.49, 130.95, 130.22, 129.22, 128.05, 127.47, 127.41, 126.36, 126.31, 124.69, 123.13, 123.07, 122.59, 122.54, 121.01, 120.95, 114.83, 114.78, 112.01, 111.97, 111.52, 111.43, 21.34, 20.63. HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{14}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$: 276.1131. Found: 276.1136.



7-bromo-3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(1*H*)-one (3ha)

Following the general procedure, the desired compound was obtained as a yellow solid, mp 291-292 °C, 54 mg, 61% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 11.87 (s, 1H), 8.95 (s, 1H), 8.88 (dd, J = 5.9, 3.4 Hz, 1H), 8.10 (t, J = 2.2 Hz, 1H), 7.66 (dt, J = 8.8, 2.3 Hz, 1H), 7.51 (td, J = 8.6, 2.6 Hz, 2H), 7.35-7.14 (m, 2H), 3.70 (s, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 153.49, 151.64, 136.38, 134.20, 133.91, 130.92, 130.36, 130.10, 126.32, 123.26, 122.75, 121.29, 116.52, 115.16, 111.98, 111.37, 29.34. HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{13}\text{BrN}_3\text{O}$ ($\text{M}+\text{H}$) $^+$: 354.0237. Found: 354.0243.



3-(1*H*-indol-3-yl)-7-(trifluoromethyl)quinoxalin-2(1*H*)-one (3ia)


Following the general procedure, the desired compound was obtained as an orange solid, mp 306-308 °C, 80 mg, 97% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 12.88 (s, 1H), 12.02 (s, 1H), 8.99 (s, 1H), 8.95-8.87 (m, 1H), 8.19 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.53 (ddd, J = 14.5, 9.7, 6.1 Hz, 2H), 7.31-7.20 (m, 2H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 154.66, 153.38, 136.44, 134.01, 133.34, 132.23, 126.26, 124.68 (q, J = 235 Hz), 124.63, 123.87, 123.63 (q, J = 33 Hz), 123.27, 122.82, 121.37, 116.24, 112.07, 111.18. HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{11}\text{F}_3\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$: 330.0849. Found: 330.0854.



3-(1*H*-indol-3-yl)-6,7-dimethylquinoxalin-2(1*H*)-one (3ja)


Following the general procedure, the desired compound was obtained as a yellow solid, mp 276-278 °C, 60 mg, 83% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 12.29 (s, 1H), 11.72 (s, 1H), 8.89 (d, J = 7.4 Hz, 2H), 7.66 (s, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.36-7.16 (m, 2H), 7.08 (s, 1H), 2.32 (d, J = 4.3 Hz, 6H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 154.55, 151.08, 137.38, 136.32, 132.58, 131.83, 131.18, 128.26,

127.77, 126.28, 123.08, 122.51, 120.87, 115.13, 111.91, 111.52, 19.82, 19.12. HRMS (ESI) m/z calculated for C₁₈H₁₆N₃O (M+H)⁺: 290.1288. Found: 290.1289.




6,7-difluoro-3-(1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ka)³

Following the general procedure, the desired compound was obtained as a dark yellow solid, mp 264-265 °C, 50 mg, 68% yield. ¹H NMR (400 MHz, d₆-DMSO) δ 12.50 (s, 1H), 11.85 (s, 1H), 8.93 (d, J = 3.0 Hz, 1H), 8.83 (dd, J = 6.4, 2.4 Hz, 1H), 7.97 (dd, J = 11.4, 8.2 Hz, 1H), 7.51 (dd, J = 6.4, 2.5 Hz, 1H), 7.30-7.13 (m, 3H). ¹³C NMR (101 MHz, d₆-DMSO) δ 154.11, 152.34, 136.39, 133.58, 131.57, 129.31, 129.21, 128.73, 127.30 (d, J = 10.4 Hz), 126.17, 123.13, 122.74, 121.21, 115.09 (d, J = 18.7 Hz), 111.99, 111.19, 102.70 (d, J = 21.1 Hz).




6,7-dichloro-3-(1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3la)

Following the general procedure, the desired compound was obtained as a dark yellow solid, mp 279-281 °C, 54 mg, 61% yield. ¹H NMR (400 MHz, d₆-DMSO) δ 12.52 (s, 1H), 11.91 (s, 1H), 8.96 (d, J = 2.9 Hz, 1H), 8.90-8.81 (m, 1H), 8.14 (s, 1H), 7.52 (dd, J = 6.2, 2.5 Hz, 1H), 7.45 (s, 1H), 7.30-7.19 (m, 2H). ¹³C NMR (101 MHz, d₆-DMSO) δ 154.44, 153.54, 136.77, 134.51, 132.83, 130.47, 129.81, 128.80, 126.52, 125.35, 123.62, 123.27, 121.79, 116.27, 112.44, 111.58. HRMS (ESI) m/z calculated for C₁₆H₁₀Cl₂N₃O (M+H)⁺: 330.0195. Found: 330.0202.



6,7-dibromo-3-(1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ma)

Following the general procedure, the desired compound was obtained as a dark yellow solid, mp 310-312 °C, 78 mg, 74% yield. ¹H NMR (400 MHz, d₆-DMSO) δ 12.48 (s, 1H), 11.90 (s, 1H), 8.96 (d, J = 3.0 Hz, 1H), 8.85 (d, J = 6.4 Hz, 1H), 8.23 (s, 1H), 7.60 (s, 1H), 7.51 (s, 1H), 7.25 (dd, J = 7.0, 3.5 Hz, 2H). ¹³C NMR (101 MHz, d₆-DMSO) δ 154.06, 153.21, 136.40, 134.15, 133.10, 131.42, 130.60, 126.15, 123.29, 122.89, 121.89, 121.42, 118.99, 116.83, 112.06, 111.25. HRMS (ESI) m/z calculated for C₁₆H₁₀Br₂N₃O (M+H)⁺: 417.9185. Found: 417.9190.





3-(1*H*-indol-3-yl)-1-((1-tosyl-1*H*-1,2,3-triazol-4-yl)methyl)quinoxalin-2(*1*H)-one (4)**


Following the general procedure, the desired compound was obtained as a pale yellow solid, mp 229–231 °C, 46 mg, 92% yield. ^1H NMR (400 MHz, d_6 -DMSO) δ 11.83 (s, 1H), 8.90 (s, 3H), 7.99 (d, J = 8.3 Hz, 2H), 7.94 (d, J = 7.7 Hz, 1H), 7.56–7.46 (m, 5H), 7.38 (t, J = 7.5 Hz, 1H), 7.29–7.21 (m, 2H), 5.67 (s, 2H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, d_6 -DMSO) δ 153.56, 150.74, 147.85, 143.23, 136.35, 133.38, 133.31, 132.18, 130.89, 130.73, 130.59, 128.64, 128.36, 128.28, 127.39, 126.33, 123.88, 123.68, 123.02, 122.62, 121.10, 114.51, 111.95, 111.37, 37.31, 21.31. HRMS (ESI) m/z calculated for $\text{C}_{26}\text{H}_{21}\text{N}_6\text{O}_3\text{S} (\text{M}+\text{H})^+$: 497.1390. Found: 497.1398.


6. Copies of NMR spectra for prepared compounds


3-(1*H*-indol-3-yl)quinoxalin-2(*H*)-one (3aa)




3-(1-methyl-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3ab**)**


3-(2-methyl-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3ac**)**


3-(2-phenyl-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ad)

3-(5-methoxy-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ah)


3-(5-(benzyloxy)-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ai)


3-(5-fluoro-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3aj)




3-(5-chloro-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3ak)


3-(6-chloro-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3al)




3-(7-methyl-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3am**)**


3-(7-methoxy-1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3an)

3-(7-(benzyloxy)-1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3ao)




3-(1*H*-pyrrol-3-yl)quinoxalin-2(*1*H)-one (3ap)**


3-(1-methyl-1*H*-pyrrol-3-yl)quinoxalin-2(*H*)-one (3aq)




3-(2,4-dimethyl-1*H*-pyrrol-3-yl)quinoxalin-2(*H*)-one (3ar)





3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(*H*)-one (3ba)




1-benzyl-3-(1*H*-indol-3-yl)quinoxalin-2(*H*)-one (3ca)




3-(1*H*-indol-3-yl)-1-(prop-2-yn-1-yl)quinoxalin-2(*1*H)-one (3da)**


6-chloro-3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(*H*)-one (3ea)

6-bromo-3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(*1H*)-one (3fa)



3-(1*H*-indol-3-yl)-6-methylquinoxalin-2(*1H*)-one (3ga)


3-(1*H*-indol-3-yl)-7-methylquinoxalin-2(*1H*)-one (3ga')




7-bromo-3-(1*H*-indol-3-yl)-1-methylquinoxalin-2(*H*)-one (3ha)

3-(1*H*-indol-3-yl)-7-(trifluoromethyl)quinoxalin-2(*H*)-one (3ia)





3-(1*H*-indol-3-yl)-6,7-dimethylquinoxalin-2(*1H*)-one (3ja)

6,7-difluoro-3-(1*H*-indol-3-yl)quinoxalin-2(*H*)-one (3ka)




6,7-dichloro-3-(1*H*-indol-3-yl)quinoxalin-2(1*H*)-one (3la)



6,7-dibromo-3-(1*H*-indol-3-yl)quinoxalin-2(*1H*)-one (3ma)

3-(1*H*-indol-3-yl)-1-((1-tosyl-1*H*-1,2,3-triazol-4-yl)methyl)quinoxalin-2(*H*)-one (4)



7. References:

1. M. Noikham, T. Kittikool and S. Yotphan, Iodine-Catalyzed Oxidative Cross-Dehydrogenative Coupling of Quinoxalinones and Indoles: Synthesis of 3-(Indol-2-yl)quinoxalin-2-one under Mild and Ambient Conditions, *Synthesis*, 2018, **50**, 2337.
2. Y.-Y. Han, Z.-J. Wu, X.-M. Zhang and W.-C. Yuan, An Efficient Synthesis of 3-(Indol-3-yl)quinoxalin-2-ones with TfOH-catalyzed Friedel–Crafts Type Coupling Reaction in Air, *Tetrahedron Lett.*, 2010, **51**, 2023.
3. Y. A. Azev, O. S. Ermakova, V. S. Berseneva, V. A. Bakulev, M. A. Ezhikova and M. I. Kodess, Synthesis of Fluoroquinoxalin-2(1H)-one Derivatives Containing Substituents in the Pyrazine and Benzene Fragments, *Russ. J. Org. Chem.*, 2017, **53**, 90.